Zogenix, Inc. (NASDAQ:ZGNX) represented a move of 2.37 percent or $-1.3 per share and closed its previous day trading session at $38.95. 526836 Shares were traded in the last trading session with an Average Volume of 683.72 Million Shares. The stock currently has a Market Capitalization of 1.22 Billion.
Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel? DosePro? is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA.
The stock traded between $ 8.50 and $43.35 over 1-Year time period showing its price to sales ratio of 58.52. Zogenix, Inc. (NASDAQ:ZGNX) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $4.69 and 200-Day Simple Moving Average of $56.75. Its Price to Free Cash Flow is 0 and Price to Book of 16.65.
Analyst’s recommended the stock as 1.5 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Zogenix, Inc. (NASDAQ:ZGNX) reported its Actual EPS of $-1.68/share. The analysts offering Earnings Estimates for the company were believing that Zogenix, Inc. could bring EPS of $-0.93/share. The difference between Actual EPS and Estimated EPS was -0.75 Percent. Thus showing an Earnings Surprise of -80.6 Percent.
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)
In the last trading session, Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) added its value by 3.48% closing at the price of $35.04. The stock currently has market capitalization of 831.5 Million, with average volume of 909.1 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is showing beta of 1.13. This particular value of beta suggests that Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has historically moved 113% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is at $-3.36.
The stock currently has RSI of 46.68. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) topped its 52-week high price of $44.00 on 01/24/18 and 52-Week Low Price of $13.50 on 08/16/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 8.83% and monthly volatility of 7.80% respectively.